Protocol measures antiviral activity and cytotoxicity against EV-D68 in Rhabdomyosarcoma cells, suggesting potential treatment options.
The following is a protocol for live virus antiviral screening against EV-D68 in vitro using Rhabdomyosarcoma (RD) cells. RD Cells are prophylactically treated with antiviral candidates that have been serially diluted to investigate activity, via IC50 values generated via analysis of immunofluorescent staining, against EV-D68. You may opt to include PgP inhibitor in the assay by adding 2uM into the infection media. Each live virus screening assay is accompanied by a matching cytotoxicity screening assay in uninfected cells to investigate drug toxicity.
No takes yet. Share an insight, caveat, or question.
Pearl et al. (2025) studied this question.